Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -

NCT02203760 is registered in ClinicalTrials.gov with North Eastern German Society of Gynaecological Oncology as lead sponsor.

NCT NCT02203760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02203760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 16, 2019
Completion date
December 31, 2024
Enrollment
58 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma or carcinosarcoma